August 11, 2020

The Niche

Knoepfler lab stem cell blog

Japan Regenerative Medicine

3 min read

Every so often I realize I’ve accumulated a bunch of tabs on my browsers of things I need to dive into as time permits, which sometimes translates into a collection of recommended reads here on The Niche. Here are some recommended recent reads in the stem cell/regenerative medicine field and childhood cancer space. It includes some great science and complex social and policy developments and opinions. ‘I just want to live’: California man pleads with scientists around the world to ‘CRISPR me’. Remarkably this …Read More

2 min read

Japan is a leader in stem cell and regenerative medicine research, and in particular in clinical translation toward the bedside. Induced pluripotent stem cell (IPSC)-based investigational therapies are rightly an area of focus in Japan given their invention by Nobel Laureate Shinya Yamanaka. Small clinical studies based on IPSC have been initiated there for several diseases including related to vision loss and Parkinson’s Disease. David Cyranoski over at Nature reports on a new, different stem cell clinical effort in Japan for vision loss with …Read More

2 min read

Where do things stand with some players in the for-profit world of stem cell and cellular medicine companies? Here are a few brief news items with quick analysis. Mesoblast is dominating the news of late. Mesoblast reported good news from its Phase II safety trial for its mesenchymal progenitor cell (MPC) product in patients with Type II Diabetes. There were no treatment-related adverse outcomes and as a bonus there were hints of efficacy. Osiris Going in New Direction. Cellular medicine company Osiris has been in …Read More